Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name TAK-079
Trade Name
Synonyms TAK079|TAK 079|Mezagitamab
Drug Descriptions

TAK-079 (Mezagitamab) is a monoclonal antibody that targets CD38, which has potential cytolytic effects against CD38-expressing cells (J Immunol May 1, 2017, 198 (1 Supplement) 224.20, PMID: 32045493).

DrugClasses CD38 Antibody 9
CAS Registry Number 2227490-52-8
NCIT ID C148078


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Bortezomib + Dexamethasone + Lenalidomide + TAK-079 Bortezomib Dexamethasone Lenalidomide TAK-079 0 1
Dexamethasone + Lenalidomide + TAK-079 Dexamethasone Lenalidomide TAK-079 0 1
Dexamethasone + Pomalidomide + TAK-079 Dexamethasone Pomalidomide TAK-079 0 1
TAK-079 TAK-079 0 1
TAK-079 + TAK-981 TAK-079 TAK-981 0 1

Additional content available in CKB BOOST